PMID- 31668464
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1090-2120 (Electronic)
IS  - 0045-2068 (Linking)
VI  - 94
DP  - 2020 Jan
TI  - Structural and clinical impact of anti-allergy agents: An overview.
PG  - 103351
LID - S0045-2068(19)31323-9 [pii]
LID - 10.1016/j.bioorg.2019.103351 [doi]
AB  - Allergic disorders are markedly rising in industrialized countries. The 
      identification of compounds that trigger the immunoglobulin E (IgE)-dependent 
      allergic reaction remain the means to improve the quality of life by limiting 
      patient's exposure to critical allergens. Information concerning the treatment 
      and onset of allergic disorders including atopic dermatitis, allergic rhinitis, 
      and bronchial asthma has been provided by the research over the past decade. 
      Recent studies also indicated that allergic inflammation is associated closely 
      with their exacerbation and progression and indeed is the basic pathophysiology 
      of allergic diseases. As a result of immunological and molecular biological 
      studies our understanding of the mechanism of allergic inflammation with regard 
      to therapeutic agents has improved. While much effort has been paid to developing 
      a new anti-allergic agent, the allergic disease has yet to be completely 
      conquered. The more extensive research will allow the development of new 
      therapeutics to combat allergic diseases. Currently, with respect to mechanism of 
      action anti-allergy drugs are classified into five types including histamine H(1) 
      antagonists, leukotriene antagonists, Th(2) cytokine inhibitors, thromboxane A(2) 
      inhibitors and mediator-release inhibitors. The use of two or more anti-allergy 
      agents together is not acknowledged at present, but this will be the subject of 
      research in the future because with different mechanisms of action anti-allergy 
      agents used at the same time will theoretically increase their effects. This 
      review article focuses on anti-allergy agents highlighting their applications, 
      clinical trials and recent advancement on drugs.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Kapoor, Yagyesh
AU  - Kapoor Y
AD  - School of Pharmaceutical Sciences, Apeejay Stya University, Gurgaon, Haryana 
      122103, India.
FAU - Kumar, Kapil
AU  - Kumar K
AD  - School of Pharmaceutical Sciences, Apeejay Stya University, Gurgaon, Haryana 
      122103, India; School of Pharmacy and Technology Management, SVKM's NMIMS, 
      Hyderabad, Telangana 509301, India. Electronic address: kapil.py@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191014
PL  - United States
TA  - Bioorg Chem
JT  - Bioorganic chemistry
JID - 1303703
RN  - 0 (Anti-Allergic Agents)
SB  - IM
MH  - Anti-Allergic Agents/chemistry/*therapeutic use
MH  - Humans
MH  - Hypersensitivity/*drug therapy
OTO - NOTNLM
OT  - 5-Lipoxygenase inhibitors
OT  - Allergic disorders
OT  - Allergic inflammation
OT  - Anti-allergic drugs
OT  - Asthma
OT  - Dermatitis
OT  - FLAP inhibitors
OT  - Glucocorticoids
OT  - Histamine H(1) antagonists
OT  - IL-5 inhibitors
OT  - IgE inhibitor
OT  - Immunoglobulin E
OT  - Leukotriene antagonists
OT  - Mediator-release inhibitors
OT  - Monoclonal antibodies
OT  - Rhinitis
OT  - Th(2) cytokine inhibitors
OT  - Thromboxane A(2) inhibitors
EDAT- 2019/11/02 06:00
MHDA- 2021/02/20 06:00
CRDT- 2019/11/01 06:00
PHST- 2019/08/12 00:00 [received]
PHST- 2019/10/04 00:00 [revised]
PHST- 2019/10/08 00:00 [accepted]
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2019/11/01 06:00 [entrez]
AID - S0045-2068(19)31323-9 [pii]
AID - 10.1016/j.bioorg.2019.103351 [doi]
PST - ppublish
SO  - Bioorg Chem. 2020 Jan;94:103351. doi: 10.1016/j.bioorg.2019.103351. Epub 2019 Oct 
      14.